132 related articles for article (PubMed ID: 10776974)
1. Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.
Ychou M; Douillard JY; Rougier P; Adenis A; Mousseau M; Dufour P; Wendling JL; Burki F; Mignard D; Marty M
Am J Clin Oncol; 2000 Apr; 23(2):143-8. PubMed ID: 10776974
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
Michael M; Brittain M; Nagai J; Feld R; Hedley D; Oza A; Siu L; Moore MJ
J Clin Oncol; 2004 Nov; 22(21):4410-7. PubMed ID: 15514383
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Saliba F; Hagipantelli R; Misset JL; Bastian G; Vassal G; Bonnay M; Herait P; Cote C; Mahjoubi M; Mignard D; Cvitkovic E
J Clin Oncol; 1998 Aug; 16(8):2745-51. PubMed ID: 9704727
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
[TBL] [Abstract][Full Text] [Related]
7. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.
Karthaus M; Ballo H; Abenhardt W; Steinmetz T; Geer T; Schimke J; Braumann D; Behrens R; Behringer D; Kindler M; Messmann H; Boeck HP; Greinwald R; Kleeberg U
Oncology; 2005; 68(4-6):326-32. PubMed ID: 16020959
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
10. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
Takeda Y; Kobayashi K; Akiyama Y; Soma T; Handa S; Kudoh S; Kudo K
Int J Cancer; 2001 Apr; 92(2):269-75. PubMed ID: 11291056
[TBL] [Abstract][Full Text] [Related]
11. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.
Kee BK; Morris JS; Slack RS; Crocenzi T; Wong L; Esparaz B; Overman M; Glover K; Jones D; Wen S; Fisch MJ
Support Care Cancer; 2015 Mar; 23(3):661-70. PubMed ID: 25160493
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Van Cutsem E; Blijham GH
Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
[TBL] [Abstract][Full Text] [Related]
14. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P
J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350
[TBL] [Abstract][Full Text] [Related]
15. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA
Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.
Gibbs P; Clingan PR; Ganju V; Strickland AH; Wong SS; Tebbutt NC; Underhill CR; Fox RM; Clavant SP; Leung J; Pho M; Brown TJ
Cancer Chemother Pharmacol; 2011 Jan; 67(1):153-63. PubMed ID: 20333384
[TBL] [Abstract][Full Text] [Related]
20. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
Fuchs CS; Moore MR; Harker G; Villa L; Rinaldi D; Hecht JR
J Clin Oncol; 2003 Mar; 21(5):807-14. PubMed ID: 12610178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
